Epistem

Epistem is a United Kingdom contract research organisation (CRO) headquartered in Manchester. Founded in 2000, the company provides preclinical and clinical laboratory services, research models and analytical platforms that support decision making across drug discovery, development and the early clinical pipeline. Its stated mission is to accelerate therapies to market by providing innovative and dependable solutions to complex biomedical challenges, and its vision is to innovate unique solutions to biomedical challenges through defining expertise. Epistem's preclinical offering spans both in vitro and in vivo models, with a focus on oncology and inflammatory diseases, and extensive experience in the gastrointestinal disease area, including GI toxicities. The company also offers organoid models for the modelling of complex physiological systems and diseases, and specialist research areas including inflammatory bowel disease, dermatology, immune cell assays, biodefence and GI toxicity and mucositis. Its GCLP-accredited laboratories support clinical trials, providing histology, immunohistochemistry (IHC) and image analysis, gene expression and DNA genotyping services. Among its named service platforms are RNAscope in situ hybridisation services, high-throughput PCR, next-generation sequencing (NGS), histology and immunohistochemistry, bioinformatics, and a plucked hair biomarker platform. Epistem's RNAscope work is performed in a GCLP-accredited and HTA-registered laboratory on FFPE tissue, fully automated on the Ventana Discovery Ultra platform, with multiplex labelling and digital quantification using the Aperio ScanScope platform. Its bioinformatics service provides in-house analysis of NGS data, including raw data QC, genome alignment, differential gene expression, pathway analysis and biomarker signature identification. Epistem states that it has worked with over 200 pharmaceutical and biotechnology companies. It describes itself as a privately owned company following a management buy-out in 2018, and continues to develop innovative and clinically relevant assays and models in-house and through collaboration with commercial and academic partners. The company positions itself on reliable, innovative and transferable models, platforms and services, with custom protocols and personalised services delivered by an experienced technical team.

Epistem was founded in 2000 and is headquartered in Manchester, United Kingdom. From its base in Manchester, the company built a contract research business serving the pharmaceutical and biotechnology industries, providing preclinical and clinical laboratory services, research models and analytical platforms. Over its history Epistem developed a portfolio of research models and service platforms spanning in vitro and in vivo models, with particular strength in oncology, inflammatory diseases and the gastrointestinal disease area including GI toxicities. It also built GCLP-accredited laboratory capabilities supporting clinical trials, including histology, immunohistochemistry and image analysis, gene expression and DNA genotyping. The company states that it has worked with over 200 pharmaceutical and biotechnology companies. A significant turning point came in 2018 with a management buy-out, after which Epistem continued as a privately owned company. Following the buy-out, the company continued to invest in innovative and clinically relevant assays and models, both through in-house development and through collaboration with commercial and academic partners. Its service portfolio expanded to include organoid models for complex physiological systems and diseases, RNAscope in situ hybridisation services performed in a GCLP-accredited and HTA-registered laboratory, high-throughput PCR, next-generation sequencing, bioinformatics and a plucked hair biomarker platform. Epistem describes its mission as accelerating therapies to market by providing innovative and dependable solutions to complex biomedical challenges, and its vision as innovating unique solutions to biomedical challenges through defining expertise. The company continues to position itself as a specialist provider of reliable, innovative and transferable models, platforms and services supporting decision making throughout the drug discovery, development and early clinical pipeline.

• 2018

  Management buy-out; Epistem continues as a privately owned company.

• 2000

  Epistem founded.

A specialist contract research organisation offering reliable, innovative and transferable models, platforms and services across drug discovery, development and early clinical stages, with custom protocols and personalised services.

• RNAscope services

  Contract RNAscope in situ hybridisation services performed on FFPE tissue in a GCLP-accredited and HTA-registered laboratory, fully automated on the Ventana Discovery Ultra platform, with multiplex labelling and digital quantification using the Aperio ScanScope platform.

• Bioinformatics services

  In-house bioinformatic analysis of next-generation sequencing data, including demultiplexing and raw data QC, genome alignment, identification of differentially expressed genes, pathway analysis and biomarker signature identification and assessment.

• Organoid models

  Organoid models for the modelling of complex physiological systems and diseases.

• Histology and immunohistochemistry

  GCLP-accredited histology, IHC and image analysis services supporting clinical trials.

• Plucked hair biomarker platform

  A biomarker platform offered among Epistem's specialist research services.

1. 1Homepage - epistemepistem.co.uk
2. 2About Us Epistem contract Research Services - epistemepistem.co.uk
3. 3RNAscope Services | Bespoke Solutions - epistemepistem.co.uk
4. 4Bioinformatics services | Data Analysis and Biological Interpretation - epistemepistem.co.uk
5. 5Epistem (United Kingdom) - Wikidatawikidata.org